VODG - Vitro Diagnostics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.2985
-0.0113 (-3.65%)
As of 3:30PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.3098
Open0.0000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume35,571
Market Cap7.203M
Beta3.77
PE Ratio (TTM)N/A
EPS (TTM)-0.0210
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • ACCESSWIRE2 months ago

    Vitro Bio-Pharma 2nd Quarter Ended April 30th 2018 Financial Results of Operations

    GOLDEN, CO / ACCESSWIRE / June 26, 2018 / Vitro Diagnostics, Inc. (VODG), dba Vitro BioPharma, announced its 2nd quarter ended April 30th 2018 financial results of operations. Vitro Diagnostics Inc. (''Vitro'') is pleased to announce a record 2nd quarter in Stem Cell Revenues. Vitro recorded 2nd quarter revenues of $125,886 vs $56,633 an increase of 222% over the same comparative quarter last year.

  • ACCESSWIRE3 months ago

    Vitro Bio-Pharma Debt Re-Capitalization and Executive Team Formation

    GOLDEN, CO / ACCESSWIRE / May 3, 2018 / Vitro Diagnostics, Inc. (VODG), dba Vitro BioPharma, announced today the details of its balance sheet re-capitalization and the formation of its executive team effective April 30th 2018. The company reorganized $1,003,119 of the company's founder and C.E.O. advances to the company that were advanced during the Research and Development years of the company over the last ten plus years. As previously announced the company has entered into the commercialization of its Stem Cell Therapies and is growing the companies operating business with new Stem Cell clinics, physicians and patients.

  • ACCESSWIRE5 months ago

    Vitro Bio-Pharma 1st Quarter 2018 Financial Results of Operations

    GOLDEN, CO / ACCESSWIRE / March 23, 2018 / Vitro Diagnostics, Inc. (OTC PINK: VODG), dba Vitro BioPharma, announced its 1st quarter ended January 31st, 2018 financial results of operations. Vitro Diagnostics ...

  • ACCESSWIRE8 months ago

    2017 CEO Shareholder Letter: Translation from R&D to Stem Cell Therapies Accelerates Revenue and Prospects for Future Growth

    GOLDEN, CO / ACCESSWIRE / December 20, 2017 / Vitro Diagnostics, Inc. (OTC PINK: VODG), dba Vitro Biopharma , announced its CEO letter to its shareholders, including discussion of 2016 & 2017 results, ...

  • ACCESSWIRE9 months ago

    Vitro Biopharma Files Patent for Its Novel Stem Cell Line with Broad Application to Stem Cell Therapies

    GOLDEN, CO / ACCESSWIRE / November 21, 2017 / Vitro Diagnostics, Inc. (OTC PINK: VODG), dba Vitro Biopharma, announced the filing of a USPTO patent application regarding a novel stem cell line and its ...